Key statistics
On Friday, MaxCyte Inc (MYE0:FRA) closed at 3.28, 27.13% above the 52 week low of 2.58 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.30 |
---|---|
High | 3.30 |
Low | 3.28 |
Bid | 3.46 |
Offer | 3.62 |
Previous close | 3.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 105.30m |
Free float | 98.63m |
P/E (TTM) | -- |
Market cap | 389.61m USD |
EPS (TTM) | -0.3408 USD |
Data delayed at least 15 minutes, as of Oct 11 2024 14:29 BST.
More ▼
Announcements
- MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
- MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
- MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
- MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
- MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
- MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
- MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
- MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
- MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
More ▼